RxDoctor Payments Data

Nikolaos Tsiouris, MD

Cardiovascular Disease · Las Vegas, NVNPI 1790789428

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Biotronik Inc. at 49.5% of the total. 2025 is the largest year on record at $10,992, more than ten times the $528 reported in 2019.

$19,139in general payments, 2019–2025

Across 154 payments — averaging $124.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$9K
  • Abbott$8K
  • Sanofi-aventis U.S. LLC$437
  • Novartis$373
  • Astellas Pharma US Inc$236
  • Vifor Pharma, Inc.$200
  • plus $786 from 15 others

What the payments were for

  • Consulting fees$7,25038%
  • Speaking & faculty fees$3,00016%
  • Travel & lodging$5,48229%
  • Food & beverage$3,21017%
  • Education$1981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,139 in reported general payments places this provider in the 85th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$330,906
Medicare patients
1,031
Services billed
3,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban235$230,861
EntrestoSacubitril/Valsartan142$153,316
XareltoRivaroxaban53$62,305
MultaqDronedarone Hcl22$32,046
FarxigaDapagliflozin Propanediol26$23,263
BrilintaTicagrelor14$6,970
Repatha SureclickEvolocumab11$6,343
Mexiletine Hcl35$4,026
Metoprolol Succinate176$2,628
Amiodarone Hcl63$1,385
Digoxin23$938
Diltiazem 24hr Er (Cd)Diltiazem Hcl25$825
Carvedilol119$652
Lisinopril102$479
Metoprolol Tartrate83$448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$194$230,861235 claims
NovartisEntresto$373$153,316142 claims
Johnson & JohnsonXarelto$15$62,30553 claims
Sanofi-aventis U.S. LLCMultaq$437$32,04622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →